卢廷旺

[摘要] 目的 分析糖尿病代谢性白内障合并屈光不正治疗的安全性水平。方法 选择该院于2018年1月—2019年5月收治的132例糖尿病代谢性白内障合并屈光不正患者为研究对象，随机分成对照组、观察组，给予两组常规小切口囊外切除联合人工晶体植入术治疗、超声乳化吸除联合人工晶体植入术治疗。结果 观察组疗效与对照组比较差异无统计学意义（P>0.05）;观察组并发症发生率低于对照组（P<0.05）;观察组手术切口及手术时间均优于对照组（P<0.05）。结论 糖尿病代谢性白内障并屈光不正治疗中，超声乳化吸除联合人工晶体植入术的效果可靠，安全性高。

[关键词] 糖尿病代谢性白内障;屈光不正;超声乳化吸除术

[Abstract] Objective To analyze the safety level of diabetic metabolic cataract combined with refractive error treatment. Methods A total of 132 patients with diabetic metabolic cataract and refractive error who were treated in the hospital from January 2018 to May 2019 were selected as the research subjects. They were randomly divided into the control group and the observation group. Intraocular lens implantation， phacoemulsification and intraocular lens implantation. Results There was no statistically significant difference in the efficacy between the observation group and the control group（P>0.05）. The incidence of complications in the observation group was lower than that in the control group（P<0.05）. The surgical incision and operation time in the observation group were better than those in the control group（P<0.05）. Conclusion In the treatment of diabetic metabolic cataract and refractive error， phacoemulsification combined with intraocular lens implantation is reliable and safe.

[Key words] Diabetic metabolic cataract; Refractive error; Phacoemulsification

近年来，糖尿病代谢性白内障发病率逐渐升高[1]。这种糖尿病并发症的发生会对患者的视功能及日常生活带来诸多不良影响[2]。而当糖尿病代谢性白内障患者合并屈光不正后，患者的视力恢复难度明显升高。因此，该文选取2018年1月—2019年5月收治的132例患者，分析糖尿病代谢性白内障并屈光不正患者的治疗，现报道如下。

1  资料与方法

1.1  一般资料

选择该院于收治的132例糖尿病代谢性白内障合并屈光不正患者为研究对象。随机分成对照组（66例）和观察组（66例）。对照组男36例，女30例;年龄（49.6±8.4）岁;患眼共78只。观察组男37例，女29例;年龄（49.9±8.6）岁;患眼共80只，以上差异无统计学意义（P>0.05）。

1.2  方法

对照组接受常规治疗：给予患者小切口囊外摘除联合人工晶体植入术治疗。①术前血糖控制。自糖尿病代谢性白内障并屈光不正患者入院起，常规监测患者的血糖水平，根据患者的血糖监测结果，实施降糖干预，直至患者的三餐前血糖值控制于6～8 mmol/L水平為止。②术前……